Quantcast
Last updated on April 19, 2014 at 17:21 EDT

Latest Olanzapine Stories

2011-09-27 16:50:00

ROCKVILLE, Md., Sept. 27, 2011 /PRNewswire-USNewswire/ -- There is little evidence to support the use of atypical antipsychotic drugs for some treatments other than their officially approved purposes, even though many clinicians continue to commonly prescribe these drugs for so-called "off label" uses, according to a new report from the U.S. Department of Health and Human Services' (HHS) Agency for Healthcare Research and Quality (AHRQ). An article based on information in the report will...

2011-09-27 18:09:48

A review of previous studies suggests that even though atypical antipsychotic medications are commonly used for off-label conditions such as behavioral symptoms of dementia, anxiety, and obsessive-compulsive disorder, these medications are effective for only a few off-label conditions, and that the benefits and harms of these medications for these uses vary, according to an article in the September 28 issue of JAMA. "Atypical antipsychotic medications are approved for marketing and...

2011-09-27 18:07:21

Medical evidence suggests that psychiatric drugs known as atypical antipsychotics are effective in reducing symptoms for some off-label conditions, but not others, according to a new RAND Corporation study. Evidence supports the effectiveness of some atypical antipsychotics in reducing symptoms of generalized anxiety disorder, obsessive-compulsive disorder, post-traumatic stress disorder and behavioral symptoms in elderly patients with dementia, although significant side effects were...

2011-07-12 12:37:36

New clinical research findings explain why antipsychotic drug treatment can cause weight gain and increase the risk of type 2 diabetes Research to be presented at the upcoming annual meeting of the Society for the Study of Ingestive Behavior (SSIB), the foremost society for research into all aspects of eating and drinking behavior, may explain why some antipsychotic drugs can promote overeating, weight gain, and insulin resistance. Olanzapine, an atypical antipsychotic drug approved by the...

2011-04-11 07:00:00

TITUSVILLE, N.J., April 11, 2011 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) on April 6 approved INVEGA® (paliperidone) extended-release tablets for the treatment of schizophrenia in adolescents 12 to 17 years of age. The efficacy of INVEGA® to treat schizophrenia in adolescents was established in one six-week clinical study. INVEGA® is an atypical antipsychotic medication and was first approved in the U.S. in December...

2011-02-07 21:50:30

A warning issued by the Food and Drug Administration regarding the use of atypical antipsychotics for the treatment of dementia was associated with a significant decline in the use of these medications for treating dementia symptoms in elderly patients, according to a report in the February issue of Archives of General Psychiatry, one of the JAMA/Archives journals. "In 2001, more than 70 percent of U.S. atypical antipsychotic prescriptions were written for off-label indications such as...

2011-02-07 21:39:18

Prescriptions of second-generation medications were already declining before FDA 'black box' warning, according to U-M analysis As loved ones with dementia disappear into symptoms of aggression, agitation or delusions, families are left with few good medical solutions. A new generation of antipsychotic medications gained popularly in the 1990s because they avoided side effects such as Parkinson's syndrome associated with conventional antipsychotic medications used to treat dementia. But a new...

2011-02-02 09:12:00

LONDON, February 2, 2011 /PRNewswire/ -- Thirteen US blockbusters will lose patent protection over the next two years, data from EvaluatePharma show, highlighting the challenges facing the pharmaceutical industry in the coming years. With the reporting season in full swing it is no wonder that several big pharmaceutical company chief executives have warned of tough times ahead. - Drugs worth $15.3bn face generic competition this year - "At risk" sales to more than double to...

475adc8e9acf5b0b636c6cdc4ca90bb2
2011-01-11 14:00:00

Eli Lilly and Co. will join forces with German drugmaker Boehringer Ingelheim to develop diabetes treatments, as the U.S. pharmaceutical company pushes to fill a looming revenue gap created by expiring patents for several key drugs. Lilly will pay Boehringer Ingelheim $387.4 million as part of a joint bid to develop and sell up to five drugs.  The two companies will split revenues from any approved drugs, not counting costs for making and selling the product.  Each drugmaker will...

2011-01-10 08:54:23

(Ivanhoe Newswire) -- Top-selling drugs, known as atypical antipsychotic medications, lack evidence that they'll actually be beneficial, according to a new study. Drugs in this class may cause serious effects such as weight gain, diabetes, and heart disease, along with costing Americans billions of dollars. "Because these drugs have safety issues, physicians should prescribe them only when they are sure patients will get substantial benefits," Randall Stafford, M.D., Ph.D., associate...